EP1344533A1 — Pharmaceutical compositions comprising mannose binding lectin
Assigned to NatImmune AS · Expires 2003-09-17 · 23y expired
What this patent protects
The present invention relates to pharmaceutical compositions comprising MBL and/or MBL variants. In particular the invention relates to pharmaceutical compositions comprising at least 200 µg/ml protein containing material, wherein mannan binding lectin (MBL) and/or MBL variants c…
USPTO Abstract
The present invention relates to pharmaceutical compositions comprising MBL and/or MBL variants. In particular the invention relates to pharmaceutical compositions comprising at least 200 µg/ml protein containing material, wherein mannan binding lectin (MBL) and/or MBL variants constitutes at least 35% (w/w) of the total protein; or to compositions comprising at least 400 µg/ml mannan binding lectin (MBL) and/or MBL variants. In addition the invention relates to pharmaceutical compositions comprising MBL and/or MBL variants and divalent cations. The invention also describes methods of preparing said compositions. The pharmaceutical compositions according to the invention may for example be used in methods of treatment of a number of different clinical conditions including infections. Uses of the compositions for preparation of medicaments for treatment of a clinical condition are also described.
Drugs covered by this patent
- Ozempic (semaglutide) · Novo Nordisk
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.